MAP2K7 and melanoma: Recent data showed that TERT promoter mutations, in BRAF-mutant melanoma cell lines, were associated with sensitivity to BRAF and MEK inhibitors highlighting a link between the expression of telomerase and sensitivity to targeted therapy [7].